These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 33408716)

  • 1. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
    Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
    Front Immunol; 2020; 11():601497. PubMed ID: 33408716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and nanoengineering approaches towards activatable cancer immunotherapy.
    Zhang C; Pu K
    Chem Soc Rev; 2020 Jul; 49(13):4234-4253. PubMed ID: 32452475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology synergized immunoengineering for cancer.
    Chauhan DS; Dhasmana A; Laskar P; Prasad R; Jain NK; Srivastava R; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharm Biopharm; 2021 Jun; 163():72-101. PubMed ID: 33774162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized Interleukin-12 for Cancer Immunotherapy.
    Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA
    Front Immunol; 2020; 11():575597. PubMed ID: 33178203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing cancer immunotherapy with nanomedicine.
    Irvine DJ; Dane EL
    Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor associated macrophages: The new challenge for nanomedicine.
    Andón FT; Digifico E; Maeda A; Erreni M; Mantovani A; Alonso MJ; Allavena P
    Semin Immunol; 2017 Dec; 34():103-113. PubMed ID: 28941641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
    Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
    Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microenvironment-Enabled Nanotherapy.
    Wang L; Huo M; Chen Y; Shi J
    Adv Healthc Mater; 2018 Apr; 7(8):e1701156. PubMed ID: 29283221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology.
    Li W; Wei H; Li H; Gao J; Feng SS; Guo Y
    Nanomedicine (Lond); 2014 Nov; 9(16):2587-605. PubMed ID: 25490427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.
    Duan X; Chan C; Lin W
    Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gold nanoparticle mediated cancer immunotherapy.
    Almeida JP; Figueroa ER; Drezek RA
    Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
    Huang KW; Hsu FF; Qiu JT; Chern GJ; Lee YA; Chang CC; Huang YT; Sung YC; Chiang CC; Huang RL; Lin CC; Dinh TK; Huang HC; Shih YC; Alson D; Lin CY; Lin YC; Chang PC; Lin SY; Chen Y
    Sci Adv; 2020 Jan; 6(3):eaax5032. PubMed ID: 31998834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy.
    Jia R; Teng L; Gao L; Su T; Fu L; Qiu Z; Bi Y
    Int J Nanomedicine; 2021; 16():1525-1551. PubMed ID: 33658782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.